Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder.
Recommended Citation
Vetterlein MW, Karabon P, Dalela D, Jindal T, Sood A, Seisen T, Trinh QD, Menon M, and Abdollah F. Impact of baseline characteristics on the survival benefit of high-intensity local treatment in metastatic urothelial carcinoma of the bladder. Eur Urol Focus 2018; 4(4):568-571.
Document Type
Article
Publication Date
7-1-2018
Publication Title
Eur Urol Focus
Abstract
A recent study reported an overall survival benefit for patients with metastatic urothelial carcinoma of the bladder (mUCB) managed with high-intensity local treatment (LT) of the primary tumor (chemotherapy plus radical cystectomy and/or radiation therapy ≥50Gy). Given the non-negligible morbidity of these procedures, adequate patient selection is crucial. Our objective was to identify patients who might benefit the most from high-intensity LT. Data for 3044 patients with mUCB at diagnosis were extracted from the National Cancer Data Base 2004-2013, and patients were categorized on the basis of treatment: high-intensity LT versus conservative LT (chemotherapy plus transurethral resection of bladder tumor and/or radiation therapy <50Gy). Multivariate Cox regression analysis predicted baseline 2-yr overall mortality (OM) risk among patients who received conservative LT. We then assessed the interaction between predicted OM risk and LT type. Compared to conservative LT, high-intensity LT yielded a higher observed OM-free survival rate among all patients with pure mUCB, irrespective of their predicted OM risk (nonsignificant interaction, p=0.7). These findings underline the need for further retrospective and prospective evaluation. PATIENT SUMMARY: Among patients with metastatic histologically pure urothelial carcinoma of the bladder, we found an overall survival benefit of high-intensity local treatment directed at the primary tumor, regardless of predicted baseline 2-yr overall mortality risk.
Medical Subject Headings
Aged; Carcinoma, Transitional Cell; Chemoradiotherapy, Adjuvant; Cystectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome Assessment (Health Care); Patient Selection; Risk Assessment; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms
PubMed ID
28753834
Volume
4
Issue
4
First Page
568
Last Page
571
